205 related articles for article (PubMed ID: 34263366)
1. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?
Botty van den Bruele A; Ferraro E; Sevilimedu V; Hogan MP; Javed-Tayyab S; Le T; Fornier MN; Morrow M; Sacchini V
Breast Cancer Res Treat; 2021 Sep; 189(2):307-315. PubMed ID: 34263366
[TBL] [Abstract][Full Text] [Related]
2. Preoperative factors that predict pathologic nodal involvement in early-stage HER2+ breast cancer: selecting cT1cN0 patients for treatment with neoadjuvant chemotherapy versus upfront surgery.
Faleh S; Prakash I; Salehi A; Khan H; Basik M; Boileau JF; Tejera D; Panet F; Martel K; Meterissian S; Wong SM
Breast Cancer Res Treat; 2024 Jun; 205(2):303-312. PubMed ID: 38381275
[TBL] [Abstract][Full Text] [Related]
3. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
4. Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy.
Rajan KK; Boersma C; Beek MA; Berendsen TA; van der Starre-Gaal J; Kate MV'V; Francken AB; Noorda EM
Breast Cancer Res Treat; 2024 Feb; 203(3):477-486. PubMed ID: 37923963
[TBL] [Abstract][Full Text] [Related]
5. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
[TBL] [Abstract][Full Text] [Related]
6. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
Zeidman M; Schmidt H; Alberty-Oller JJ; Pisapati KV; Ahn S; Mazumdar M; Ru M; Moshier E; Port E
Breast Cancer Res Treat; 2021 May; 187(1):177-185. PubMed ID: 33392839
[TBL] [Abstract][Full Text] [Related]
7. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
9. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
11. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
[TBL] [Abstract][Full Text] [Related]
14. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.
Kuzucan A; Chen JH; Bahri S; Mehta RS; Carpenter PM; Fwu PT; Yu HJ; Hsiang DJ; Lane KT; Butler JA; Feig SA; Su MY
Clin Breast Cancer; 2012 Apr; 12(2):110-8. PubMed ID: 22444717
[TBL] [Abstract][Full Text] [Related]
16. Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy.
Weiss A; Lee KC; Romero Y; Ward E; Kim Y; Ojeda-Fournier H; Einck J; Blair SL
Ann Surg Oncol; 2014 Oct; 21(10):3310-6. PubMed ID: 25056851
[TBL] [Abstract][Full Text] [Related]
17. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
18. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
An YY; Kim SH; Kang BJ
World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer.
Ragusi MA; Winter-Warnars GA; Wesseling J; Linn SC; Beets-Tan RG; van der Velden BH; Elias SG; Gilhuijs KG; Loo CE
Br J Radiol; 2021 Jul; 94(1123):20201125. PubMed ID: 34142870
[TBL] [Abstract][Full Text] [Related]
20. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?
Segara D; Krop IE; Garber JE; Winer E; Harris L; Bellon JR; Birdwell R; Lester S; Lipsitz S; Iglehart JD; Golshan M
J Surg Oncol; 2007 Nov; 96(6):474-80. PubMed ID: 17640031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
